Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8847825 | 0.79 | SMN1; SMN2 (0.30) | — | |
| SCHEMBL14351412 | 0.78 | HCAR2 (0.36) | ELANE | |
| SCHEMBL2822436 | 0.77 | TSHR (0.39) | — | |
| SCHEMBL28440469 | 0.77 | ELANE (0.33) | ELANECA1CA2CA7 | |
| SCHEMBL7604391 | 0.75 | TSHR (0.42) | ELANECA1CA2CA7 | |
| SCHEMBL7606341 | 0.75 | TSHR (0.42) | ELANECA1CA2CA7 | |
| SCHEMBL7602361 | 0.75 | TSHR (0.42) | ELANECA1CA2CA7 | |
| SCHEMBL15424713 | 0.75 | ELANE (0.32) | ELANECA1CA2CA7 | |
| SCHEMBL3895101 | 0.75 | PRKCA (0.41) | — | |
| SCHEMBL13647265 | 0.73 | CA12 (0.32) | ELANECA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1371646-B1 | ARYL-SUBSTITUTED ALICYCLIC COMPOUND AND MEDICAL COMPOSITION COMPRISING THE SAME | DAINIPPON SUMITOMO PHARMA CO (JP) | 2010-05-19 | — | — | EP | disclosed |
| US-7601728-B2 | Bicyclic pyrrole derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20090192129-A1 | BICYCLIC PYRROLE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090149483-A1 | BICYCLIC PYRROLE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-06-11 | — | — | US | disclosed |
| US-20080318922-A1 | Bicyclic Pyrrole Derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1829877-A1 | BICYCLIC PYRROLE DERIVATIVES | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-7176199-B2 | Aryl-substituted alicyclic compound and medical composition comprising the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20040106622-A1 | Aryl-substituted alicylic compound and medical composition comprising the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1371646-A1 | ARYL-SUBSTITUTED ALICYCLIC COMPOUND AND MEDICAL COMPOSITION COMPRISING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-12-17 | — | — | EP | disclosed |
| US-5614519-A | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists | KARL THOMAE GMBH (DE) | 1997-03-25 | — | — | US | disclosed |
| EP-0552765-B1 | Benzimidazoles, pharmaceutical compositions containing them and process for their preparation | THOMAE GMBH DR K (DE) | 1996-08-14 | — | — | EP | disclosed |
| US-5482948-A | Pyridyl derivatives and pharmaceutical compositions comprising these compounds | DR. KARL THOMAE GMBH (DE) | 1996-01-09 | — | — | US | disclosed |
| US-5459147-A | Angeotensin-antagonistic effects; hypotensive, antiischemic, and antidiabetic agents, treating glaucoma | DR. KARL THOMAE GMBH (DE) | 1995-10-17 | — | — | US | disclosed |
| EP-0547517-B1 | Pyridyl derivatives, medicines containing these compounds and processes for their preparation | THOMAE GMBH DR K (DE) | 1995-05-17 | — | — | EP | disclosed |
| EP-0581166-A1 | Benzimidazoles, process for their preparation and their use as angiotensin-II antagonists | Dr. Karl Thomae GmbH (DE) | 1994-02-02 | — | — | EP | disclosed |
| EP-0566020-A1 | Benzimidazoles, pharmaceutical compositions thereof and processes for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-10-20 | — | — | EP | disclosed |
| EP-0560330-A2 | Substituted benzimidazolyl derivatives, therapeutic agents containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-09-15 | — | — | EP | disclosed |
| EP-0556789-A2 | Substituted biphenyl derivatives, therapeutic agents containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-08-25 | — | — | EP | disclosed |
| EP-0552765-A1 | Benzimidazoles, pharmaceutical compositions containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-07-28 | — | — | EP | disclosed |
| EP-0547517-A1 | Pyridyl derivatives, medicines containing these compounds and processes for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318922-A1 | Bicyclic Pyrrole Derivatives | DPP4, DPP7, DPP3 | ELANE 3216/4885CA1 1194/4885CA2 988/4885 |
| US-20090192129-A1 | BICYCLIC PYRROLE DERIVATIVES | DPP4, DPP7, DPP3 | ELANE 3723/4885CA1 1451/4885CA2 869/4885 |
| US-20090149483-A1 | BICYCLIC PYRROLE DERIVATIVES | DPP4, DPP7, DPP3 | ELANE 3723/4885CA1 1451/4885CA2 869/4885 |
| US-20040106622-A1 | Aryl-substituted alicylic compound and medical composition comprising the same | ITGB3, ITGB1, ITGAL | ELANE 1779/4885CA1 3206/4885CA2 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.